Quantitative tests of liver function measure hepatic improvement after sustained virological response: Results from the HALT-C trial

Alimentary Pharmacology and Therapeutics

Volumn 29, Issue 5, 2009, Pages 589-601

  Everson, G T ^a,b   Shiffman, M L ^c   Hoefs, J C ^d,h   Morgan, T R ^d,h   Sterling, R K ^c   Wagner, D A ^e   Desanto, J L ^b   Curto, T M ^f   Wright, E C ^g  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e METABOLIC SOLUTIONS INC   (United States)

^f NEW ENGLAND RESEARCH INSTITUTES   (United States)

^g NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^h VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CHOLIC ACID; GALACTOSE; LIDOCAINE; METHIONINE; PEGINTERFERON; PHENAZONE; RIBAVIRIN; TECHNETIUM SULFUR COLLOID TC 99M;

ADULT; ARTICLE; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER METABOLISM; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RIBAVIRIN; STATISTICS AS TOPIC;

EID: 59149088404     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03908.x     Document Type: Article

References (36)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New Engl J Med 1999 341 : 556 62.
2. Armstrong GL, Simard EP, Wasley A, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus (HCV) infection in the United States, 1999-2002 (abstract). Ann Intern Med 2006 144 : 705 714.
3. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997 26 (Suppl. 1 62S 5S.
4. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000 31 : 777 82.
5. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortalty, and costs in the United States. Am J Public Health 2000 90 : 1562 9.
6. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002 36 : S35 46.
7. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000 20 : 17 35.
8. Afdahl NH. The natural history of hepatitis C. Semin Liv Dis 2004 24 : 3 8.
9. Seeff LB, Hollinger FB, Alter HJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B hepatitis: a National Heart, Lung and Blood Institute collaborative study. Hepatology 2001 33 : 455 63.
10. El Serag. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004 127 : S27 34.
11. National Institutes of Health Consensus Development Conference statement: management of hepatitis C 2002: June 10-12, 2002. Hepatology 2002 36 : S3 220.
12. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001 358 : 958 65.
13. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
14. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 55.
15. Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C Trial. Hepatology 2006 44 : 1675 84.
16. Everson GT, Trotter JF, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005 42 : 255 62.
17. Everson GT. Treatment of hepatitis C in the patient with decompensated cirrhosis. Clin Gastroenterol Hepatol 2005 3 : S106 12.
18. Lee WM, Dienstag JL, Lindsay KL, et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 2004 25 : 472 92.
19. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C The PEG-FIBROSIS Project Group. Gastroenterology 2002 122 : 1303 13.
20. Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004 39 : 333 42.
21. Huang JF, Yu ML, Lee CM, et al. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. Aliment Pharmacol Ther 2007 25 : 1029 37.
22. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007 45 : 579 87.
23. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007 147 : 677 84.
24. Arase Y, Ikeda K, Suzuki F, et al. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection. J Med Virol 2007 79 : 1485 90.
25. Arase Y, Ikeda K, Suzuki F, et al. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 2007 79 : 1095 102.
26. Everson GT, Shiffman ML, Morgan TR, et al. The spectrum of hepatic functional impairment in patients with fibrosis and compensated cirrhosis due to chronic hepatitis C: results from the HALT-C Trial. Aliment Pharmacol Ther 2008 27 : 798 809.
27. Everson GT, Martucci MA, Shiffman ML, et al. Portal systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt. Aliment Pharmacol Ther 2007 26 : 401 10.
28. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995 22 : 696 9.
29. SAS Institute, Inc. SAS/STAT® 9.1 User's Guide. Cary, NC : SAS Institute, Inc., 2004.
30. Rosner B. Fundamentals of Biostatistics, 3rd edn. Belmont, CA : Duxbury Press, 1990.
31. Shrestha R, McKinley C, Showalter R, et al. Quantitative Liver Function Tests (QLFTs) define the functional severity of liver disease in early stage cirrhosis. Liver Transpl Surg 1997 3 : 166 73.
32. Tanaka E, Kurata N, Yasuhara H. How useful is the 'cocktail approach' for evaluating human drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo? J Clin Pharm Ther 2003 28 : 157 65.
33. Wojcicki J, Kozlowski K, Drozdzik M, Wojcicki M. Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis. Eur J Drug Metab Pharmacokinet 2002 27 : 243 7.
34. Reichel C, Nacke A, Sudhop T, et al. The low-dose monoethylglycinexylidide test: assessment of liver function with fewer side effects. Hepatology 1997 25 : 1323 7.
35. Ocker M, Ganslmayer M, Zopf S, et al. Improvement of quantitative testing of liver function in patients with chronic hepatitis C after installment of antiviral therapy. World J Gastroenterol 2005 11 : 5521 4.
36. Rincon D, Ripoll C, Lo Iacono O, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006 101 : 2269 74.